第17届国际恶性淋巴瘤会议：主要收获。

IF 11.5 Q1 HEMATOLOGY

Blood Cancer Discovery Pub Date : 2023-09-01 DOI:10.1158/2643-3230.BCD-ND2023-0003

{"title":"第17届国际恶性淋巴瘤会议：主要收获。","authors":"","doi":"10.1158/2643-3230.BCD-ND2023-0003","DOIUrl":null,"url":null,"abstract":"The 17th International Conference on Malignant Lymphoma (ICML) took place in Lugano, Switzerland, from June 13-17 this year. The conference has been held every 2 to 3 years since its inception in 1981 and has become a significant and influential gathering for lymphoma researchers from around the world, this year hosting 4,761 registered attendees. Here, we provide some highlights of what we felt were the most noteworthy findings, both clinical and pre-clinical, across various lymphoma entities, presented at the 17th ICML.","PeriodicalId":29944,"journal":{"name":"Blood Cancer Discovery","volume":"4 5","pages":"342-345"},"PeriodicalIF":11.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487293/pdf/","citationCount":"0","resultStr":"{\"title\":\"17th International Conference on Malignant Lymphoma: Key Takeaways.\",\"authors\":\"\",\"doi\":\"10.1158/2643-3230.BCD-ND2023-0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The 17th International Conference on Malignant Lymphoma (ICML) took place in Lugano, Switzerland, from June 13-17 this year. The conference has been held every 2 to 3 years since its inception in 1981 and has become a significant and influential gathering for lymphoma researchers from around the world, this year hosting 4,761 registered attendees. Here, we provide some highlights of what we felt were the most noteworthy findings, both clinical and pre-clinical, across various lymphoma entities, presented at the 17th ICML.\",\"PeriodicalId\":29944,\"journal\":{\"name\":\"Blood Cancer Discovery\",\"volume\":\"4 5\",\"pages\":\"342-345\"},\"PeriodicalIF\":11.5000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487293/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/2643-3230.BCD-ND2023-0003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/2643-3230.BCD-ND2023-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

第17届国际恶性淋巴瘤大会于今年6月13日至17日在瑞士卢加诺举行。自1981年成立以来，该会议每2至3年举行一次，已成为世界各地淋巴瘤研究人员的一次重要而有影响力的聚会，今年共有4761名注册与会者。在这里，我们提供了一些我们认为在第17届ICML上发表的各种淋巴瘤实体的临床和临床前最值得注意的发现的亮点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

17th International Conference on Malignant Lymphoma: Key Takeaways.

The 17th International Conference on Malignant Lymphoma (ICML) took place in Lugano, Switzerland, from June 13-17 this year. The conference has been held every 2 to 3 years since its inception in 1981 and has become a significant and influential gathering for lymphoma researchers from around the world, this year hosting 4,761 registered attendees. Here, we provide some highlights of what we felt were the most noteworthy findings, both clinical and pre-clinical, across various lymphoma entities, presented at the 17th ICML.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood Cancer Discovery Multiple-

CiteScore

12.70

自引率

1.80%

发文量

139

期刊介绍： The journal Blood Cancer Discovery publishes high-quality Research Articles and Briefs that focus on major advances in basic, translational, and clinical research of leukemia, lymphoma, myeloma, and associated diseases. The topics covered include molecular and cellular features of pathogenesis, therapy response and relapse, transcriptional circuits, stem cells, differentiation, microenvironment, metabolism, immunity, mutagenesis, and clonal evolution. These subjects are investigated in both animal disease models and high-dimensional clinical data landscapes. The journal also welcomes submissions on new pharmacological, biological, and living cell therapies, as well as new diagnostic tools. They are interested in prognostic, diagnostic, and pharmacodynamic biomarkers, and computational and machine learning approaches to personalized medicine. The scope of submissions ranges from preclinical proof of concept to clinical trials and real-world evidence. Blood Cancer Discovery serves as a forum for diverse ideas that shape future research directions in hematooncology. In addition to Research Articles and Briefs, the journal also publishes Reviews, Perspectives, and Commentaries on topics of broad interest in the field.